



UCLA

The utility of Alternative Testing Strategies in Nanotechnology Health and Safety



The California NanoSystems Institute (CNSI)

188,000 sq. ft. facility with research labs, technology centers, start-up incubator, administrative support, conferencing and interaction space



*Nano-Go
NCN-HIR
NHIR*

Copyright 2017 – The Regents of the University of California. All Rights Reserved.

André Nel M.B.,Ch.B; M.D.
*Distinguished Professor of Medicine and Chief of NanoMedicine
Associate Director of the California NanoSystems Institute
Director UC Center for the Environmental Implications of Nanotechnology
Associate Editor ACS Nano*


Nano EHS



Pristine Materials
New properties
“New chemical substances”
Case-by-case chem tox
Descriptive animal studies



Mechanism-based screening
HTS & profiling of categories
Tiered testing approaches
Nano-enabled & composites









What are relevant exposure conc's?
Aerosols - possible
Workplace monitoring for inhalants (OELs)
Biological tissue-difficult
Environment - very difficult
Instrumentation needs

Little quantitative RA
Some qualitative RA
OELs
Tiered risk assessment
Integrated approaches to decision making (IATA)


No human disease models
Progress in cellular dose calc
Occupational data - OELs
Benchmark materials
In vitro/in vivo extrapolations

Chemical Toxicity Principles not Optimal for Molecular Initiation or Triggering Events but useful for AOP assessment

Carbon as an example.....



There are Unique Nanoscale Characteristics that Contribute in a Unique Way to Trigger Molecular Injury



Nel et al. Science 2006

Nel et al. Nature Materials. 2009

The Frank R. Lautenberg Chemical Safety for the 21st Century Act (H.R. 2576), a.k.a. the TSCA Reform Bill

- Mandates, for the 1st time, the safety evaluation of all existing chemicals in commerce and industry, starting with those most likely to cause risks
- Evaluate and prioritizes new and existing chemicals against new science & risk-based safety standards, including considerations for vulnerable populations
- Require affirmative chemical/physchem data collection to support safety evaluation
- Clear and enforceable deadlines and timely action on identified risks
- Increase transparency of chemical information by limiting unwarranted claims of confidentiality, allowing appropriate sharing of confidential information
- Providing a source of funding for EPA to carry out these significant new responsibilities



June 22nd, 2016


TSCA Reform Provisions for Alternative Test Strategies

" (3D) prior to adopting a requirement for testing using vertebrate animals, the Administrator is required to take into consideration, as appropriate and to the extent practicable, reasonably available:

- (i) toxicity information;
- (ii) computational toxicology and bioinformatics;
- (iii) high-throughput screening methods and the prediction models of those methods; and
- (iv) scientifically reliable and relevant alternatives to tests on animals that would provide equivalent information."

"(4) TIERED TESTING.-


(A) IN GENERAL.-....the Administrator shall employ a tiered screening and testing process, under which the results of screening-level tests or assessments of available information inform the decision as to whether 1 or more additional tests are necessary."



UC CEIN Predictive Toxicological Modeling

1000's of new materials

Physicochemical complexity



Adverse Outcomes in Intact Animals
(limited screening capacity)

Confirm In vivo Hazard potential

ENM Libraries of different composition and accentuated Physchem Properties

Cellular or Bio-molecular Endpoints
(High content screening)

SARs
(pathophysiology of disease)

SARs
(molecular events nano/bio interface)

Dosimetry

Pathways Of Toxicity

Dosimetry

Nel et al. Nature Material, 2009
Xia et al, ACS Nano, 2008
Xia et al. ACS Nano. 2011

George et al. ACS Nano. 2010
George et al. ACS Nano. 2011
George et al JACS 2011

Lin et al. ACS Nano. 2011
Xia et al ACS Nano. 2009
Zhang et al ACS Nano 2011

Wang et al. ACS Nano. 2010
Wang et al ACS Nano. 2011

Organization for Predictive Toxicological Research UC CEIN


Nanomaterial libraries

Compositional
Metal Oxides
Metals
CNTs

Property accentuation
Size, Shape, AR
Dissolution
Band gap


Commercial nanoproducts

High throughput screening




Cells, bacteria, yeasts, zebrafish embryos

In silico decisions, in vitro ranking



Risk Identification and decision making to

- Reduce risk
- Influence governance
- Dosimetry calculations
- Safer design



*Prioritize
Compare
Speed up*

*Validate
Dosimetry
Refine*

*Organism
Animal testing*


In vivo hazard ranking

Tools to establish Predictive Models



High Throughput Screening




Composition and Combinatorial ENM Libraries



Pathways of Toxicity




Epifluorescence




Computational analysis




Heat map ranking




From Pathways of Toxicity to Adverse Outcome Pathways




Redox activity and ROS
e.g., TiO₂, CuO, CoO




Dissolution, shedding toxic ions, e.g., ZnO, CuO




Cationic toxicity, e.g., cationic NH₂-polystyrene, PEI-Si



Inflammasome activation
e.g., High aspect ratios




Bandgap & Photoactivation
e.g., Transition MOX's



Membrane Lysis
e.g., fumed SiO₂,


Adverse Outcome Pathway

Adverse Outcome Pathways: A Framework for Organizing Information for Predictive Toxicological Modeling




Combines information from multiple fields of inquiry to illuminate knowledge of biological pathways, highlight species differences or similarities, identify research needs, and support regulatory decisions.


Adapted from Kristie Sullivan, Physicians Committee for Responsible Medicine



AOPs link Molecular and Mechanistic events to Integrated Approaches to Testing and Assessment (IATA) that can be supported by High Throughput Screening and Computational Modeling for Regulatory Purposes




Flow diagram of the steps in the AOP pathway, MIE and Key Events associated with Skin Sensitization




(adapted from OECD & Landsiedel et al)

Example Cosmetic Chemical Test Series:


- Non-cosmetic chemicals
 - Actives
 - Dyes
 - Fragrances
 - Preservatives
 - Surfactants
- cosmetic chemicals



AOPs and Regulatory Use





Possible AOPs for Carbon Nanotubes




Integrated Approaches to Testing and Assessment

(inhalation exposures)



MIE
AOPs –mechanistic
Tiered Testing
IATA

Predictive Toxicological Paradigm for CNT Lung Toxicity Assessment




Tier 1
(in vitro)

Wang et al. ACS Nano. 2010
Wang et al ACS Nano. 2011
Wang et al ACS Nano 2015


Tier 2
(in vivo)



Comparison of MWCNT Surface Charge to validate that Cellular Assays (Tier 1) reflect Lung Injury Outcome (Tier 2)

(not logistically feasible to test this in a 90 day study)



*Confocal to show
Lysosomal damage*





CNT Tiered Testing Approach


Tier 1 Testing (ATS)
 (macrophages, macrophage/epithelial co-culture)
 IL-1β
 TGF-β1
 PDGF

Tier 2 Testing
 (short term animal exposure)
 AOP-based
 Histology (fibrosis)
 Lung collagen content
 Lavage fluid cytokines


90-Day Inhalation (Tier 3)
 Descriptive apical outcome, non-mechanistic

Tier 1 Testing of 18 CNTs: US, China and EU

Tier 1: IL-1 β values (pg/ml)



Tier 3: 90 day inhalation study (EU Materials)



- | | |
|---|---|
| 1 | As-purchased (AP) crude MWCNT |
| 2 | Pluronic F108 coated AP-MWCNT (neg control) |
| 3 | MWCNT-COOH (XXX) |
| 4 | XXX (MWCNT) |
| 5 | XXX (MWCNT) |
| 6 | XXX (SWCNT) |
| 7 | XXX (SWCNT) |
| 8 | XXX (MWCNT) |
| 9 | Mitsui (MWCNT-7) |

- | | |
|----|------------------------------|
| 10 | EU NM- XXX (MWCNT) |
| 11 | EU NM- XXX (MWCNT) |
| 12 | EU NM- XXX (MWCNT) |
| 13 | EU NM- XXX (MWCNT) |
| 14 | XXX MWCNT (China) |
| 15 | Short carboxyl MWCNT (China) |
| 16 | Long carboxyl MWCNT (China) |
| 17 | SWCNT (China) |
| 18 | SWCNT (China) |
- NanoReg JRC

Physchem properties

- Aspect ratio/length
- Aggregation
- Colloidal stability
- Surface reactivity
- ROS
- Coating

MIE
Lysosomal uptake and damage

CNT AOP

AOP



Chronic lung damage
Granulomatous inflammation
Fibrosis

KE-1

Macrophage danger signal,
Inflammasome,
Chronic inflammation
IL-1 β

KE-2

Cellular co-operation
EMT
TGF- β
PDGF-AA

KE-3

Myofibroblast proliferation
ECM deposition
SMAD signal

KE Test 1

KE Test 2


KE Test 3

CNT Data Bank


MWCNT	Raw MWCNTs	
	Purified MWCNTs	
MWCNT	Long vs short	
	Functionalized	
	-PEG (-)	
	-NH ₂ (+/-)	
MWCNT	-sw-NH ₂ (++)	
	-PEI (+++)	
	SG65	
SWCNT	Arc	Raw-SWCNT Purified -metallic vs semiconductor
	Hipco	
	Different coatings	
SWCNT & MWCNT		

Integrated Approaches to Testing and Assessment (IATA) framework for CNTs

(Inhalation exposure)



Proposal how to incorporate ATS data in a decision-tree to categorize CNTs by a tiered testing approach



Nanomaterial Categorization for Assessing Risk Potential To Facilitate Regulatory Decision-Making

Hilary Godwin,^{1,2,3,4,5,6,7} Catherine Nameth,³ David Avery,³ Lynn L. Bergeson,¹ Daniel Bernard,⁸ Elizabeth Beryl,^{9,10} William Boyes,¹¹ Scott Brown,¹² Amy J. Clippinger,¹³ Yoram Cohen,^{14,15} Maria Doa,¹⁶ Christine Olgivie Hendren,¹⁷ Patricia Holder,¹⁸ Keith Houck,¹⁹ Agnes B. Kane,²⁰ Frederick Kliesing,^{21,22} Tavo Kodas,²³ Robert Landsiedel,²⁴ Isaac Lynch,²⁵ Timothy Malloy,^{26,27,28,29} Mary Beth Miller,³⁰ Julie Muller,³¹ Gunter Oberdorster,³² Eijah J. Pedersen,³³ Richard C. Phelan,³⁴ Phillip Sayre,^{35,36} Yvicki Stone,³⁷ Kristie M. Sullivan,³⁸ Jutta Tentschert,³⁹ Philip Wallis,⁴⁰ and Andre E. Nel^{41,42,43,44}

¹Department of Environmental Health Sciences, Fielding School of Public Health, Institute of the Environment and Sustainability, University of California Center for Environmental Implications of Nanotechnology, and California Nanosystems Institute, University of California, Los Angeles, California 90095, United States; ²Bergeson & Campbell, P.C., Washington, D.C. 20007, United States; ³OD Nanosafety Platform, GrandPré, France; ⁴UCLA School of Public Affairs, University of California, Los Angeles, California 90095, United States; ⁵Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States; ⁶Durham Central Research & Development, DuPont Biomass Technologies, E.I. du Pont de Nemours and Company, Wilmington, Delaware 19883, United States; ⁷PEA International Science Consultants Ltd., London, United Kingdom; ⁸Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California 90095, United States; ⁹Office of Pollution Prevention and Toxicity, U.S. Environmental Protection Agency, Washington, D.C. 20460, United States; ¹⁰Center for the Environmental Implications of Nanotechnology, Duke University, Durham, North Carolina 27708, United States; ¹¹Boise School of Environmental Science and Management, University of California, Santa Barbara, California 93106, United States; ¹²Brown University, Providence, Rhode Island 02912, United States; ¹³Pennsylvania Bio-Nano Systems, Doylestown, Pennsylvania 18001, United States; ¹⁴Calot Corporation, Boston, Massachusetts 02130, United States; ¹⁵Department of Technology and Ecology, BASF SE, 67056 Ludwigshafen am Rhein, Germany; ¹⁶School of Geography, Earth & Environmental Science, University of Birmingham, Edgbaston B15 2TT, United Kingdom; ¹⁷University of California School of Law, Los Angeles, California 90005, United States; ¹⁸Applied Nanomaterial Solutions, L.L.C., Carlsbad/Marble Company, Carlsbad, Maryland 21220, United States; ¹⁹Nanosol, Luxembourg, Belgium; ²⁰University of Rochester, Rochester, New York 14627, United States; ²¹Material Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States; ²²Genentech, Inc., Seattle, Washington 98101, United States; ²³School of Life Sciences, Heriot-Watt University, Edinburgh EH14 4AS, United Kingdom; ²⁴Physicians Committee for Responsible Medicine, Washington, D.C. 20016, United States; ²⁵Federal Institute for Risk Assessment, Berlin, Germany; ²⁶Novartis Nanotechnology, Novartis, CH-4002 Basel, Switzerland; ²⁷Center for Nanobiology and Predictive Toxicology and ²⁸Department of Medicine, Division of Nanomedicine, University of California, Los Angeles, California 90095, United States

Multistakeholder Group. ACS Nano. 2015

Metal Oxide MIE's and AOPs in Lung Toxicity

ZnO
CuO

Fe₂O₃
Fe₃O₄
WO₃
TiO₂
Al₂O₃
SiO₂

CoO
Co₃O₄
Cr₂O₃
Mn₂O₃
Ni₂O₃

CeO₂, Eu₂O₃
Gd₂O₃, HfO₂,
La₂O₃, Sb₂O₃,
Sb₂O₃, SnO₂,
Yb₂O₃, Er₂O₃
Y₂O₃, ZrO₂

Spherical
vs
nanorod
CeO₂ & TiO₂

SiO₂
-fumed
-amorphous
-mesoporous
-crystalline


Soluble
Metal oxides

Transition MOX's


Rare Earth
Oxides

High Aspect
Ratio


Surface
reactivity
(silanols)




Disrupt Redox equilibrium
Oxidative stress



NLRP3
inflammasome
Autophagy
interference




NLRP3
inflammasome
Sub-acute
inflammation




Membrane lysis
(acute)
NLRP3 (sub-acute)

Nel et al. Science 2006
Nel et al. Nature Materials. 2009


Use of Individual or Converging AOPs for the Toxicological Profiling of Metal Oxide Nanoparticles




Test method prioritization



Separate pathways /different doses




Converging key events




Predictive Toxicology Approaches allows Large Numbers of Materials to be Profiled for Inhalation Tox Decisions

Transition MOx's

CoO
Co₃O₄
Cr₂O₃
Mn₂O₃
Ni₂O₃
etc




ZnO
CuO
Ag



CeO₂ Gd₂O₃
La₂O Sb₂O₃
Yb₂O₃ Y₂O₃



Rare Earth Oxides

High and Low Temp Silicas




siloxane rings

Graphene




Lipid BL




Phosphate complexation



NLRP3



SWCNT & MWCNT




LAR Metals/MOx)

- MWCNTs, SWCNTs
- Graphene
- Fullerenes
- Metal Oxides
- Commercial Cu and CuO
- Silica and Fumed silica
- ZnO
- Nano Ag
- Semiconductor III-V, Mox's
- REOs
- Quantum dots
- Composites/Release

George et al. ACS Nano. 2010
Xia et al. ACS Nano. 2011
Zhang et al. ACS Nano. 2012
Nel et al. ACR. 2012 26

NanoDatabank, Data Analytics and NanoEHS Decision Support Tools (www.nanoinfo.org)

*Input raw Data, shared findings using Centralized Nanodatabank
Estimate releases of ENMS, fate & transport analysis, analyze HTS data, toxicity predictions and decision analysis support tools*



Pitfalls of Alternative Test Strategies

- *ATS* do not comprehensively capture biological processes in the context of intact organs or whole organisms
- *In vitro/in vivo* disconnect (*offset by AOPs as intellectual constructs*)
- Biased or incomplete coverage of injury response pathways
- False positives and false negatives
- Does not cover toxicokinetics and ADME
- No real-life exposure scenarios, including use of unrealistic dosimetry
- Only tests acute toxicological events, not chronic or repetitive exposures

CEIN Broad Capabilities for Implementing the use of ATS for Nano EHS Assessment and Governance

- Predictive toxicological profiling of individual and broad material categories (data bank, comparison grid, modeling)
- Use of AOPs and HTS to assist data collection for IATA and regulatory decision making
- Assist industry in developing new integrated test strategies for emerging nano-enabled materials and nano-composites
- Tailor experimentation to relevance of potential exposures
- Safer design principles based on structure-activity analysis
- Simulations, modeling, LCA

ATS at the R&D and Design Stage

- Demonstrate whether change in manufacturing process alters biological response
- Adjust surface chemistry or coating on “new grade” material to match registered “base” material
- Demonstrate “equivalency” to an approved competitor product (or benchmark materials)
- Could examine “extremes” in a CNT-family to develop ranges on which SNURs are based
 - E.g., Company X 12 MWCNTs (4 PMN-numbers)

The Story about the CNT Commercial Enterprise




(2015)





- Over expectation/hype
- Over production relevant to demand
- Technical issues: purity, crosslinking
- Incorporation into other products
- Risk avoidance
- Risk perception: “the next asbestos”

Will History Repeat Itself for Graphene?



Nature Nanotechnology, October, 2014




The trajectory of graphene is following a similar path to carbon nanotubes with patents being filed at an even quicker rate.

Graphene SAR Analysis as the basis for ATS, AOPs and Predictive Toxicological Paradigms

Planar surface hydrophobicity

Hydrophilic edge effects, Flake sizes



Graphene flakes behave as colloids as well as 2D planar surfaces

Planar surface hydrophobicity


Membrane damaging AOPs (for ATS)

Surface functionalities (COOH, Epoxy, OH)


Carbonyl radicals




*Membrane lysis
Lipid peroxidation
Membrane destructive lipid extraction*



Cellular uptake



Lysosomal AOP





Inflammasome

*IL-1 β
(CNT Tier 1)*


*Wang et al ACS Nano 2015
Hurt R et al Chem Soc Review 2016
Hersam Lab North-Western*

UC CEIN - A Multidisciplinary Workforce

Chemistry/ Material Science



MSSR/ High Throughput



Social Science



Ecology/ Environmental Science




Law/Policy



Public Health



Engineering



Biology/Tox/Medicine



Computational Modeling

